Ki-67 labeling index as an independent prognostic factor in human esophageal squamous cell carcinoma

Esophagus

Volumn 9, Issue 4, 2012, Pages 195-202

  Sasagawa, Hisami ^a   Shiozaki, Atsushi ^a   Iitaka, Daisuke ^a   Ichikawa, Daisuke ^a   Komatsu, Shuhei ^a   Fujiwara, Hitoshi ^a   Okamoto, Kazuma ^a   Nakashima, Shingo ^a   Kinoshita, Osamu ^a   Murayama, Yasutoshi ^a   Kuriu, Yoshiaki ^a   Ikoma, Hisashi ^a   Nakanishi, Masayoshi ^a   Ochiai, Toshiya ^a   Kokuba, Yukihito ^a   Otsuji, Eigo ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Esophageal cancer; Ki 67 labeling index; Prognostic factor

Indexed keywords

BIOLOGICAL MARKER; KI 67 ANTIGEN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CELL COUNTING; CELL PROLIFERATION; CLINICAL ARTICLE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MALE; MEDIAN SURVIVAL TIME; PROGNOSTIC ASSESSMENT; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR GROWTH; TUMOR VOLUME;

EID: 84862981084     PISSN: 16129059     EISSN: 16129067     Source Type: Journal    
DOI: 10.1007/s10388-012-0336-6     Document Type: Article

References (20)

1. Daly JM, Fry WA, Little AG, Winchester DP, McKee RF, Stewart AK, et al. Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg. 2000;190:562–73.
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.
3. Ozawa S, Tachimori Y, Baba H, Fujishiro M, Matsubara H, Numasaki H, et al. Comprehensive registry of esophageal cancer in Japan, 2003. Esophagus. 2011;8:9–29.
4. Ando N, Ozawa S, Kitagawa Y, Shinozawa Y, Kitajima M. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg. 2000;232:225–32.
5. Nakagawa S, Kanda T, Kosugi S, Ohashi M, Suzuki T, Hata-keyama K. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg. 2004;198:205–11.
6. Shimada H, Kitabayashi H, Nabeya Y, Okazumi S, Matsubara H, Funami Y, et al. Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery. 2003;133:24–31.
7. Kunisaki C, Makino H, Takagawa R, Yamamoto N, Nagano Y, Fujii S, et al. Surgical outcomes in esophageal cancer patients with tumor recurrence after curative esophagectomy. J Gastrointest Surg. 2008;12:802–10.
8. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710–5.
9. Youssef EM, Matsuda T, Takada N, Osugi H, Higashino M, Kinoshita H, et al. Prognostic significance of the MIB-1 proliferation index for patients with squamous cell carcinoma of the esophagus. Cancer. 1995;76:358–66.
10. Ikeda G, Isaji S, Chandra B, Watanabe M, Kawarada Y. Prognostic significance of biologic factors in squamous cell carcinoma of the esophagus. Cancer. 1999;86:1396–405.
11. Sarbia M, Bittinger F, Porschen R, Dutkowski P, Torzewski M, Willers R. Br J Cancer. 1996;74:1012–6.
12. Chino O, Osamura Y, Kise Y, Nishi T, Shimada H, Tanaka M, et al. Acceleration of the proliferative activity of esophageal carcinoma with invasion beyond the muscularis mucosae; immunohistochemical analysis using MIB-1 for the Ki-67 antigen. Tokai J Exp Clin Med. 2007;32:115–20.
13. Porschen R, Kriegel A, Langen C, Classen S, Hilse M, Lohe B, et al. Assessment of proliferative activity in carcinomas of the human alimentary tract by Ki-67 immunostaining. Int J Cancer. 1991;47:686–91.
14. Imdahl A, Jenkner J, Ihling C, Rückauer K, Farthmann EH. Is MIB-1 proliferation index a predictor for response to neoadjuvant therapy in patients with esophageal cancer? Am J Surg. 2000; 179:514–20.
15. Sobin L, Gospodarowicz M, Wittekind C, editors. TNM Classification of malignant tumors. 7th ed. Hoboken: Wiley.; 2009.
16. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983;31:13–20.
17. Al-Sheneber IF, Shibata HR, Sampalis J, Jothy S. Prognostic significance of proliferating cell nuclear antigen expression in colorectal cancer. Cancer. 1993;71:1954–9.
18. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer. 1993;71:2454–60.
19. Kubota Y, Petras RE, Easley KA, Bauer TW, Tubbs RR, Fazio VW. Ki-67-determined growth fraction versus standard staging and grading parameters in colorectal carcinoma. A multivariate analysis. Cancer. 1992;70:2602–9.
20. Tachibana M, Kinugasa S, Yoshimura H, Shibakita M, Tonomoto Y, Dhar DK, et al. Clinical outcomes of extended esophagectomy with three-field lymph node dissection for esophageal squamous cell carcinoma. Am J Surg. 2005;189:98–109.